260 related articles for article (PubMed ID: 33568750)
1. Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer.
Armstrong AJ; Li X; Tucker M; Li S; Mu XJ; Eng KW; Sboner A; Rubin M; Gerstein M
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):786-793. PubMed ID: 33568750
[TBL] [Abstract][Full Text] [Related]
2. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
3. Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies.
Weiss S; Lamy P; Rusan M; Nørgaard M; Ulhøi BP; Knudsen M; Kassentoft CG; Farajzadeh L; Jensen JB; Pedersen JS; Borre M; Sørensen KD
Int J Cancer; 2024 Jul; 155(2):298-313. PubMed ID: 38602058
[TBL] [Abstract][Full Text] [Related]
4. Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer.
Rubin MA; Girelli G; Demichelis F
Eur Urol; 2016 Apr; 69(4):557-560. PubMed ID: 26563871
[TBL] [Abstract][Full Text] [Related]
5. An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer.
Dawson NA; Zibelman M; Lindsay T; Feldman RA; Saul M; Gatalica Z; Korn WM; Heath EI
Mol Cancer Ther; 2020 Jun; 19(6):1373-1382. PubMed ID: 32220973
[TBL] [Abstract][Full Text] [Related]
6. Implementing precision cancer medicine in the genomic era.
Chen HZ; Bonneville R; Roychowdhury S
Semin Cancer Biol; 2019 Apr; 55():16-27. PubMed ID: 29857039
[TBL] [Abstract][Full Text] [Related]
7. A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer.
Jiang R; Lu YT; Ho H; Li B; Chen JF; Lin M; Li F; Wu K; Wu H; Lichterman J; Wan H; Lu CL; OuYang W; Ni M; Wang L; Li G; Lee T; Zhang X; Yang J; Rettig M; Chung LW; Yang H; Li KC; Hou Y; Tseng HR; Hou S; Xu X; Wang J; Posadas EM
Oncotarget; 2015 Dec; 6(42):44781-93. PubMed ID: 26575023
[TBL] [Abstract][Full Text] [Related]
8. Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.
Gerhauser C; Favero F; Risch T; Simon R; Feuerbach L; Assenov Y; Heckmann D; Sidiropoulos N; Waszak SM; Hübschmann D; Urbanucci A; Girma EG; Kuryshev V; Klimczak LJ; Saini N; Stütz AM; Weichenhan D; Böttcher LM; Toth R; Hendriksen JD; Koop C; Lutsik P; Matzk S; Warnatz HJ; Amstislavskiy V; Feuerstein C; Raeder B; Bogatyrova O; Schmitz EM; Hube-Magg C; Kluth M; Huland H; Graefen M; Lawerenz C; Henry GH; Yamaguchi TN; Malewska A; Meiners J; Schilling D; Reisinger E; Eils R; Schlesner M; Strand DW; Bristow RG; Boutros PC; von Kalle C; Gordenin D; Sültmann H; Brors B; Sauter G; Plass C; Yaspo ML; Korbel JO; Schlomm T; Weischenfeldt J
Cancer Cell; 2018 Dec; 34(6):996-1011.e8. PubMed ID: 30537516
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy.
Huang J; Wang JK; Sun Y
Curr Opin Urol; 2013 May; 23(3):189-93. PubMed ID: 23385974
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.
Zhu J; Tucker M; Marin D; Gupta RT; Healy P; Humeniuk M; Jarvis C; Zhang T; McNamara M; George DJ; Wu Y; Lisi S; Armstrong AJ
Urol Oncol; 2019 Nov; 37(11):813.e1-813.e9. PubMed ID: 31327751
[TBL] [Abstract][Full Text] [Related]
11. Genomic sequencing in cancer.
Tuna M; Amos CI
Cancer Lett; 2013 Nov; 340(2):161-70. PubMed ID: 23178448
[TBL] [Abstract][Full Text] [Related]
12. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
13. Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity.
Løvf M; Zhao S; Axcrona U; Johannessen B; Bakken AC; Carm KT; Hoff AM; Myklebost O; Meza-Zepeda LA; Lie AK; Axcrona K; Lothe RA; Skotheim RI
Eur Urol; 2019 Mar; 75(3):498-505. PubMed ID: 30181068
[TBL] [Abstract][Full Text] [Related]
14. Whole-Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naïve, High-Risk Prostate Cancer.
Jaratlerdsiri W; Chan EKF; Gong T; Petersen DC; Kalsbeek AMF; Venter PA; Stricker PD; Bornman MSR; Hayes VM
Cancer Res; 2018 Dec; 78(24):6736-6746. PubMed ID: 30217929
[TBL] [Abstract][Full Text] [Related]
15. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract][Full Text] [Related]
16. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
Böttcher R; Kweldam CF; Livingstone J; Lalonde E; Yamaguchi TN; Huang V; Yousif F; Fraser M; Bristow RG; van der Kwast T; Boutros PC; Jenster G; van Leenders GJLH
BMC Cancer; 2018 Jan; 18(1):8. PubMed ID: 29295717
[TBL] [Abstract][Full Text] [Related]
17. Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making.
Chahal M; Pleasance E; Grewal J; Zhao E; Ng T; Chapman E; Jones MR; Shen Y; Mungall KL; Bonakdar M; Taylor GA; Ma Y; Mungall AJ; Moore RA; Lim H; Renouf D; Yip S; Jones SJM; Marra MA; Laskin J
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610392
[TBL] [Abstract][Full Text] [Related]
18. Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions.
Chalmers ZR; Burns MC; Ebot EM; Frampton GM; Ross JS; Hussain MHA; Abdulkadir SA
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):558-566. PubMed ID: 33420417
[TBL] [Abstract][Full Text] [Related]
19. Future directions for precision oncology in prostate cancer.
Mizuno K; Beltran H
Prostate; 2022 Aug; 82 Suppl 1(Suppl 1):S86-S96. PubMed ID: 35657153
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.
Wei L; Wang J; Lampert E; Schlanger S; DePriest AD; Hu Q; Gomez EC; Murakam M; Glenn ST; Conroy J; Morrison C; Azabdaftari G; Mohler JL; Liu S; Heemers HV
Eur Urol; 2017 Feb; 71(2):183-192. PubMed ID: 27451135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
